Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials-Reference-Cited by-同舟云学术

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

Published:2011-04-28 Issue:6 Volume:27 Page:1263-1271
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Signorovitch James E.¹,Wu Eric Q.¹,Betts Keith A.¹,Parikh Kejal¹,Kantor Evan¹,Guo Amy²,Bollu Vamsi K.²,Williams Denise²,Wei L.J.³,DeAngelo Daniel J.⁴

Affiliation:

1. Analysis Group, Boston, MA, USA

2. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

3. Harvard University, Boston, MA, USA

4. Dana-Farber Cancer Institute, Boston, MA, USA

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/03007995.2011.576238

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control;Scientific Reports;2024-06-25

2. A Comparison of Relative-Efficacy Estimate(S) Derived From Both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons: A Review of Matching-Adjusted Indirect Comparisons;Value in Health;2023-11

3. Matching adjusted indirect comparison of acupuncture versus fremanezumab in the preventive treatment of episodic migraine;Current Medical Research and Opinion;2023-02-08

4. A comparison of methods for enriching network meta‐analyses in the absence of individual patient data;Research Synthesis Methods;2022-05-19

5. How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments;Value in Health;2021-08